Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM-1: navitoclax plus ruxolitinib versus placebo plus ruxolitinib in myelofibrosis
MOH_2020-08-04_009142Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Navitoclax + ruxolitinib with Placebo + ruxolitinib (2 arms). Primary endpoint: Change in spleen volume. Started Aug 2020; status: active, not recruiting.
02
Drugs
navitoclaxruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2020-08-04_009142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-04_009142.